$AVTR · Avantor, Inc.
Avantor filed its 10-Q for the quarter ended September 30, 2026, reporting net sales of $1.698B (+4.6% YoY), GAAP net income of $203.4M ($0.30 diluted EPS), and gross margin of 31.5%. The company now operates under two segments: Bioscience & Medtech Products and VWR Distribution & Services. VWR drove the top-line growth but saw adjusted operating income decline 9.5% YoY to $119.4M. The balance sheet improved with total debt down to $3.684B from $3.946B at year-end 2025.
- Q3 net sales rose 4.6% YoY to $1.698B, with VWR Distribution & Services up 5.0% to $1.234B.
- GAAP net income was $203.4M ($0.30 diluted EPS), rebounding from a $711.8M loss in Q3 2025 driven by a $785M impairment charge.
- Gross margin contracted to 31.5% from 32.4% a year ago; nine-month gross profit fell $43M to $1.573B.
- VWR Distribution & Services adjusted operating income dropped 9.5% YoY to $119.4M despite revenue growth.
- Total debt declined $262.5M from year-end 2025 to $3.684B; cash rose to $464.3M from $365.4M.
Extended-hours trading shows AVTR at $16.62, down 2.95% from the regular close and 3.85% below the filing-time price, suggesting the market is reacting negatively to margin compression and VWR segment profit decline despite headline revenue growth.
Avantor's margin compression in its core distribution business, even as revenue grows, signals that the post-pandemic normalization may still be weighing on profitability despite top-line recovery.
Avantor's mid-single-digit revenue growth trails peers in the life sciences tools space, while the margin compression in its higher-multiple Bioscience & Medtech segment raises questions about the multi-year recovery narrative in bioprocessing.
Goodwill of $4.93B (42% of total assets) remains at risk if segment performance deteriorates further; the prior-year $785M impairment in Bioscience & Medtech highlights ongoing vulnerability. Foreign currency translation losses of $45.3M over nine months signal macro exposure.